BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 16778214)

  • 1. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.
    Gore SD; Baylin S; Sugar E; Carraway H; Miller CB; Carducci M; Grever M; Galm O; Dauses T; Karp JE; Rudek MA; Zhao M; Smith BD; Manning J; Jiemjit A; Dover G; Mays A; Zwiebel J; Murgo A; Weng LJ; Herman JG
    Cancer Res; 2006 Jun; 66(12):6361-9. PubMed ID: 16778214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS.
    Leone G; Voso MT; Teofili L; Lübbert M
    Clin Immunol; 2003 Oct; 109(1):89-102. PubMed ID: 14585280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of histone deacetylase and DNA methyltransferase inhibitors on the expression of the androgen receptor gene in androgen-independent prostate cancer cell lines.
    Fialova B; Smesny Trtkova K; Paskova L; Langova K; Kolar Z
    Oncol Rep; 2013 May; 29(5):2039-45. PubMed ID: 23503510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment.
    Egger G; Aparicio AM; Escobar SG; Jones PA
    Cancer Res; 2007 Jan; 67(1):346-53. PubMed ID: 17210717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zebularine inhibits human acute myeloid leukemia cell growth in vitro in association with p15INK4B demethylation and reexpression.
    Scott SA; Lakshimikuttysamma A; Sheridan DP; Sanche SE; Geyer CR; DeCoteau JF
    Exp Hematol; 2007 Feb; 35(2):263-73. PubMed ID: 17258075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome.
    Maslak P; Chanel S; Camacho LH; Soignet S; Pandolfi PP; Guernah I; Warrell R; Nimer S
    Leukemia; 2006 Feb; 20(2):212-7. PubMed ID: 16357841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia.
    Goodyear O; Agathanggelou A; Novitzky-Basso I; Siddique S; McSkeane T; Ryan G; Vyas P; Cavenagh J; Stankovic T; Moss P; Craddock C
    Blood; 2010 Sep; 116(11):1908-18. PubMed ID: 20530795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation.
    Scott SA; Dong WF; Ichinohasama R; Hirsch C; Sheridan D; Sanche SE; Geyer CR; Decoteau JF
    Leuk Res; 2006 Jan; 30(1):69-76. PubMed ID: 16043219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA methyltransferases as targets for cancer therapy.
    Ghoshal K; Bai S
    Drugs Today (Barc); 2007 Jun; 43(6):395-422. PubMed ID: 17612710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic changes in the myelodysplastic syndrome.
    Issa JP
    Hematol Oncol Clin North Am; 2010 Apr; 24(2):317-30. PubMed ID: 20359628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expression of neprilysin gene is associated with methylation and histone modification on promoter in mouse neuroblastoma Neuro-2a cells].
    Deng Y; Lu X; Liu L; Li T; Zhang Y; Guo X; Yu G
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Aug; 30(8):810-3. PubMed ID: 25108432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status of epigenetic treatment in myelodysplastic syndromes.
    Kuendgen A; Lübbert M
    Ann Hematol; 2008 Aug; 87(8):601-11. PubMed ID: 18392623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of DNA methyltransferase activates tumor necrosis factor alpha-induced monocytic differentiation in acute myeloid leukemia cells.
    Laurenzana A; Petruccelli LA; Pettersson F; Figueroa ME; Melnick A; Baldwin AS; Paoletti F; Miller WH
    Cancer Res; 2009 Jan; 69(1):55-64. PubMed ID: 19117987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation.
    Figueroa ME; Skrabanek L; Li Y; Jiemjit A; Fandy TE; Paietta E; Fernandez H; Tallman MS; Greally JM; Carraway H; Licht JD; Gore SD; Melnick A
    Blood; 2009 Oct; 114(16):3448-58. PubMed ID: 19652201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
    Giles F; Fischer T; Cortes J; Garcia-Manero G; Beck J; Ravandi F; Masson E; Rae P; Laird G; Sharma S; Kantarjian H; Dugan M; Albitar M; Bhalla K
    Clin Cancer Res; 2006 Aug; 12(15):4628-35. PubMed ID: 16899611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA methyltransferase inhibitor RG108 and histone deacetylase inhibitors cooperate to enhance NB4 cell differentiation and E-cadherin re-expression by chromatin remodelling.
    Savickiene J; Treigyte G; Jazdauskaite A; Borutinskaite VV; Navakauskiene R
    Cell Biol Int; 2012 Nov; 36(11):1067-78. PubMed ID: 22845560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.
    Griffiths EA; Gore SD
    Semin Hematol; 2008 Jan; 45(1):23-30. PubMed ID: 18179966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
    Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
    Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.
    Garcia-Manero G; Kantarjian HM; Sanchez-Gonzalez B; Yang H; Rosner G; Verstovsek S; Rytting M; Wierda WG; Ravandi F; Koller C; Xiao L; Faderl S; Estrov Z; Cortes J; O'brien S; Estey E; Bueso-Ramos C; Fiorentino J; Jabbour E; Issa JP
    Blood; 2006 Nov; 108(10):3271-9. PubMed ID: 16882711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining DNA methyltransferase and histone deacetylase inhibition to treat acute myeloid leukemia/myelodysplastic syndrome: achievements and challenges.
    Lübbert M; Kuendgen A
    Cancer; 2015 Feb; 121(4):498-501. PubMed ID: 25336205
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.